We are live on ! Find out more
B

Braslyn Portfolio holdings

AUM $7.81M
1-Year Est. Return 338.68%
This Fund
S&P 500
This Quarter Est. Return
+34.06%
1 Year Est. Return
+338.68%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$186M
AUM Growth
–
Cap. Flow
+$179M
Cap. Flow %
96.05%
Top 10 Hldgs %
100%
Holding
3
New
3
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$176M
2
INSG icon
Inseego
INSG
+$2.29M
3
TNGX icon
Tango Therapeutics
TNGX
+$234K

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 99.1%
2 Technology 0.9%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRTX
1
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$184M 98.96%
+3,135,966
New +$176M
INSG icon
2
Inseego
INSG
$122M
$1.68M 0.9%
+761,483
New +$2.29M
TNGX icon
3
Tango Therapeutics
TNGX
$4.65B
$267K 0.14%
+26,961
New +$234K

Similar funds

AMG
Ace Management Global Sao Paulo, Brazil $7.88M AUM 47.04% 1-Year Est. Return
XS
XR Securities Chicago, Illinois $5.35M AUM 26.1% 1-Year Est. Return
SFG
Susquehanna Financial Group Bala Cynwyd, Pennsylvania $10.9M AUM
CIM
Cowen Investment Management New York $12M AUM 1.47% 1-Year Est. Return
ZIMP
Zimmermann Investment Management & Planning New Cumberland, Pennsylvania $2.27M AUM 29.81% 1-Year Est. Return
RCI
Ridgeback Capital Investments Miami Beach, Florida $560K AUM
LPARFS
Leverage Partners Absolute Return Fund SPC Cayman Islands Ky1-11111, Cayman Islands $54K AUM
SC
Saltoro Capital Dallas, Texas $30K AUM 24.79% 1-Year Est. Return

Braslyn's Q4 2023 Portfolio in Review

Q4 2023 is the first quarter with a 13F filing on record for Braslyn, which disclosed 3 positions worth $186M. Its ten largest holdings account for 100% of the portfolio.

Its largest position is Mirati Therapeutics, Inc. Common Stock: 3,135,966 shares worth $184M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, followed by Technology.

  • Braslyn's largest Q4 2023 buy was Mirati Therapeutics, Inc. Common Stock: 3,135,966 shares worth $184M.
  • Braslyn's ten largest holdings make up 100% of its $186M portfolio in Q4 2023.
  • Braslyn disclosed 3 positions in Q4 2023, its first 13F filing on record.

Based on Braslyn's 13F filing for Q4 2023, filed 14 Feb 2024.